Agile Therapeutics (NASDAQ:AGRX) Shares Up 7.3%

Agile Therapeutics Inc (NASDAQ:AGRX)’s stock price shot up 7.3% on Monday . The stock traded as high as $1.20 and last traded at $1.18, 1,445,857 shares traded hands during trading. An increase of 200% from the average session volume of 481,883 shares. The stock had previously closed at $1.10.

Several brokerages have recently weighed in on AGRX. Zacks Investment Research upgraded Agile Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.25 price target for the company in a report on Tuesday, August 6th. Maxim Group set a $3.00 price target on Agile Therapeutics and gave the company a “buy” rating in a report on Monday, June 10th. Finally, ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $3.45.

The firm has a fifty day moving average price of $1.18 and a two-hundred day moving average price of $1.32. The stock has a market capitalization of $50.41 million, a P/E ratio of -2.03 and a beta of 0.38.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. As a group, analysts anticipate that Agile Therapeutics Inc will post -0.37 EPS for the current year.

Several large investors have recently modified their holdings of the company. Renaissance Technologies LLC increased its holdings in shares of Agile Therapeutics by 5.6% during the second quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock valued at $3,291,000 after acquiring an additional 120,403 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Agile Therapeutics by 129.8% during the second quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after acquiring an additional 978,672 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Agile Therapeutics by 7.9% during the second quarter. Acadian Asset Management LLC now owns 450,180 shares of the specialty pharmaceutical company’s stock valued at $657,000 after acquiring an additional 32,911 shares in the last quarter. BlackRock Inc. boosted its position in shares of Agile Therapeutics by 27.2% during the second quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock valued at $247,000 after buying an additional 36,212 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Agile Therapeutics by 2,219.3% during the second quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock valued at $108,000 after buying an additional 73,238 shares during the last quarter. Hedge funds and other institutional investors own 43.73% of the company’s stock.

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.